Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Investment
Moderna picks Kenya for African mRNA facility
by Michael McCoy
March 19, 2022
| A version of this story appeared in
Volume 100, Issue 10
Moderna says it will build a messenger RNA (mRNA) therapeutics plant in Kenya at a cost of up to $500 million. The facility will make mRNA active ingredients and could be expanded to produce finished therapies such as Moderna’s COVID-19 vaccine. The firm’s announcement advances a promise it made in October 2021 to build an mRNA facility somewhere in Africa. Last month, BioNTech, which with Pfizer produces another mRNA COVID-19 vaccine, said it would establish modular production systems in Africa.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X